CHEMBIO DIAGNOSTICS, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2009-12-17: Form 8-K; Period of report 2009-12-17; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2009-12-02: Form 8-K; Period of report 2009-12-02; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2009-11-17: Form 8-K; Period of report 2009-11-17; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2009-11-04: Form 8-K; Period of report 2009-11-04; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2009-12-17 | 8-K | 2009-12-17 | 7.01 Regulation FD Disclosure | 7.01 a) On December 16, 2009, the Registrant (“Chembio”) entered into a Firm Fixed Price Subcontract Agreement with Battelle Memorial Institute (“Battelle”) pursuant to Battelle’s prime contract with the Center for Disease Control and Prevention (“CDC”) for the development of a point-of-care (“POC”) DPP® FLU (including seasonal and novel influenza viruses) Immuno-Status Assay using Chembio proprietary DPP technology for a cost of $811,140. | form8_k.htm |
| 2009-12-02 | 8-K | 2009-12-02 | 7.01 Regulation FD Disclosure | 7.01 On December 1, 2009, the Company issued a press release entitled “Chembio Diagnostics Donates 4,500 HIV Test Kits for World AIDS Day”. | form8k.htm |
| 2009-11-17 | 8-K | 2009-11-17 | 7.01 Regulation FD Disclosure | 7.01 On November 17, 2009, the Company issued a press release entitled “Chembio Diagnostics to Present at the FDA Blood Products Advisory Committee on November 17, 2009”. | form8k.htm |
| 2009-11-04 | 8-K | 2009-11-04 | 7.01 Regulation FD Disclosure | 7.01 On November 4, 2009, the Company issued a press release entitled “Chembio Reports Third Quarter 2009 Results”. | form8_k.htm |
| 2009-10-28 | 8-K | 2009-10-28 | 7.01 Regulation FD Disclosure | 7.01 On October 27, 2009, the Company issued a press release entitled “Chembio to Host Conference Call to Discuss Third Quarter 2009 Financial Results”. | form8k.htm |
| 2009-10-20 | 8-K | 2009-10-20 | 7.01 Regulation FD Disclosure | 7.01 On October 16, 2009, the Company issued a press release entitled “Chembio Diagnostics to Provide Tuberculosis Testing Kits to Orangutan Rehabilitation Centers in Borneo and Sumatra”. | form8k.htm |
| 2009-09-29 | 8-K | 2009-09-28 | 7.01 Regulation FD Disclosure | 7.01 On September 24, 2009, the Company issued a press release entitled “Chembio CEO Featured in Newsday’s Executive Suite Column for Company’s Best Quarterly Earnings Results Despite Recession”. | form8k.htm |
| 2009-09-10 | 8-K | 2009-09-09 | 7.01 Regulation FD Disclosure | 7.01 On September 9, 2009, the Company issued a press release entitled “Chembio to Present at Rodman & Renshaw's Eleventh Annual Healthcare Conference”. | form8_k.htm |
| 2009-08-17 | 8-K | 2009-08-17 | 7.01 Regulation FD Disclosure | 7.01 On August 17, 2009, the Company posted a PowerPoint Presentation to their website entitled “Investor Presentation August 2009.” A copy of the presentation is furnished herewith as Exhibit 99.1. | form8k.htm |
| 2009-08-07 | 8-K | 2009-06-30 | 7.01 Regulation FD Disclosure | 7.01 On August 7, 2009, the Company issued a press release entitled “Chembio Reports Second Quarter 2009 Results; Company Achieves Profit for 2nd Quarter”. | form8k.htm |
| 2009-08-04 | 8-K | 2009-08-04 | 7.01 Regulation FD Disclosure | 7.01 On August 4, 2009, the Company issued a press release entitled “Chembio to Host Conference Call to Discuss Second Quarter 2009 Financial Results”. | form8k.htm |
| 2009-07-22 | 8-K | 2009-07-22 | 7.01 Regulation FD Disclosure | 7.01 On July 20, 2009, the Company issued a press release entitled “Chembio Featuring New DPP® Products at AACC Conference & CHEMBIO.COM”. | form8k.htm |
| 2009-06-29 | 8-K | 2009-06-29 | 7.01 Regulation FD Disclosure | 7.01 On June 25, 2009, the Company issued a press release entitled “Chembio Awarded Three Year $3MM NIH SBIR Phase II Grant to Complete DPP® Test for Human Leptospirosis ”. | form8k.htm |
| 2009-06-03 | 8-K | 2009-06-03 | 7.01 Regulation FD Disclosure | 7.01 On June 3, 2009, certain officers of Chembio Diagnostics, Inc. (the “Company”) intend to deliver an investor presentation that will include the slides attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached as Exhibit 99.1. | form8_k.htm |
| 2009-05-13 | 8-K | 2009-05-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 (e) Effective May 11, 2009, the Company’s Board of Directors approved the Company’s extension of the June 15, 2006 employment agreement (the “Employment Agreement”) with Lawrence A. Siebert, the Company’s President and Chief Executive Officer. 7.01 On May 11, 2009, the Company issued a press release entitled “IDRI and Chembio Collaborate to Develop a Low-cost Test for Visceral Leishmaniasis” A copy of the press release is furnished herewith as Exhibit 99.1. | form8k.htm |
| 2009-05-08 | 8-K | 2009-05-08 | 7.01 Regulation FD Disclosure | 7.01 A copy of the press release is furnished herewith as Exhibit 99.1. | form8_k.htm |
| 2009-05-06 | 8-K | 2009-05-06 | 7.01 Regulation FD Disclosure | 7.01 On May 6, 2009, the Company issued a press release entitled “Chembio to Host Conference Call to Discuss First Quarter 2009 Financial Results” A copy of the press release is furnished herewith as Exhibit 99.1. | form8k.htm |
| 2009-03-19 | 8-K | 2009-03-19 | 7.01 Regulation FD Disclosure | 7.01 On March 19, 2009, the Company issued a press release entitled “Chembio Reports 2008 Results”. | form8_k.htm |
| 2009-03-18 | 8-K | 2009-03-17 | 7.01 Regulation FD Disclosure | 7.01 On March 17, 2009, the Company issued a press release entitled “Chembio to Host Conference Call to Discuss 2008 Financial Results” A copy of the press release is furnished herewith as Exhibit 99.1. | form8_k.htm |
| 2009-03-03 | 8-K/A | 2009-03-03 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On February 16, 2009, the practice of Lazar Levine & Felix LLP (“Lazar”), an independent registered public accounting firm, was acquired by Parente Randolph, LLC (“Parente”) in a transaction pursuant to which Lazar merged its operations into Parente and certain of the professional staff and partners of Lazar joined Parente either as employees or partners of Parente. | form8_ka2.htm |
| 2009-02-26 | 8-K/A | 2009-02-26 | 4.01 Changes in Registrant's Certifying Accountant | 4.01 On February 16, 2009, the practice of Lazar Levine & Felix LLP (“Lazar”), an independent registered public accounting firm, was acquired by Parente Randolph, LLC (Parente”) in a transaction pursuant to which Lazar merged its operations into Parente and certain of the professional staff and partners of Lazar joined Parente either as employees or partners of Parente. | form8_ka.htm |
| 2009-02-23 | 8-K | 2009-02-20 | 4.01 Changes in Registrant's Certifying Accountant; 7.01 Regulation FD Disclosure | 4.01 On February 16, 2009, the practice of Lazar Levine & Felix LLP (“Lazar”), an independent registered public accounting firm, was acquired by Parente Randolph, LLC (Parente”) in a transaction pursuant to which Lazar merged its operations into Parente and certain of the professional staff and partners of Lazar joined Parente either as employees or partners of Parente. 7.01 In a previously announced agreement between Chembio and Bio-Rad Laboratories, Inc. (“Bio-Rad”), which was included on Form 8-K filed January 22, 2009, Bio-Rad was granted a license by Chembio, provided that Chembio would receive $340,000 as a license fee. | form8_k.htm |
| 2009-02-11 | 8-K | 2009-02-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On February 9, 2009, James D. Merselis, a director of Chembio Diagnostics Inc. (the “Company”), notified the Company of his resignation as a director of the Company, effective immediately. | form8_k.htm |
| 2009-02-04 | 8-K | 2009-02-03 | 7.01 Regulation FD Disclosure | 7.01 On January 29, 2009, Chembio and Bio-Rad Laboratories, Inc. (“Bio-Rad”) agreed to defer the payments due under the HIV-2 sub-license originally granted by Bio-Rad to Chembio in February 2008 to one payment due in December 2010. | form8_k.htm |
| 2009-01-22 | 8-K | 2009-01-22 | 7.01 Regulation FD Disclosure | 7.01 On January 19, 2009 Chembio granted, effective December 31, 2008, a limited exclusive license within a defined field of application for Chembio’s Dual Path Platform technology to Bio-Rad Laboratories, Inc. (“Bio-Rad”). | form8_k.htm |
| 2009-01-16 | 8-K | 2009-01-16 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 To the extent applicable, the information set forth in Item 7.01 of this 8-K hereby is incorporated by reference in this Item 2.02. 7.01 On January 14, 2009, the Company implemented payroll and other related cost reductions primarily because of reduced demand anticipated for its products from the United States President’s Emergency Plan for AIDS Relief or PEPFAR. | form8_k.htm |